Hans Eriksson

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia

John M. Kane, Aleksandar Skuban, John Ouyang et al. · Schizophrenia Research · 2015 · 322 citations

Acute Schizophrenia, Psychiatry, Psychotic Disorder +10

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice

Renzo Mancuso, Gemma Fryatt, Madeleine Cleal et al. · Brain · 2019 · 224 citations · Full text

Immunology, Cell Death, Neurochemical Biomarkers +17

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

Nizar El-Khalili, Mark Joyce, Sarah Atkinson et al. · The International Journal of Neuropsychopharmacology · 2010 · 178 citations · Full text

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial

Christoph U. Correll, Aleksandar Skuban, John Ouyang et al. · American Journal of Psychiatry · 2015 · 178 citations

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder

Michael E. Thase, James M. Youakim, Aleksandar Skuban et al. · The Journal of Clinical Psychiatry · 2015 · 171 citations